Review of Primary Outcomes from the PERSEUS Trial of Subcutaneous DARA+VRd in Transplant-Eligible Newly Diagnosed Multiple Myeloma

Opinion
Video

Review of the key primary outcome data from this trial of subcutaneous daratumumab with bortezomib, lenalidomide and dexamethasone for newly diagnosed transplant eligible multiple myeloma patients.

Case: A 54-Year-Old Woman with Newly Diagnosed Multiple Myeloma (NDMM)

Clinical Presentation:

  • FH is a 54-year-old woman who presents to her physician with complaints of back pain, fatigue, nausea, constipation, and occasional, but recurring dizziness

Initial Clinical Workup and Diagnosis:

  • Hb 7.0 g/dL
  • Calcium 11.3 mg/dL
  • Creatinine, 1.5 mg/dL
  • Albumin, 3.2 g/dL
  • β2-microglobulin, 6.0 mg/dL
  • LDH 200 U/L
  • Bone marrow biopsy showed monoclonal plasma cells, 22%.
  • Serum monoclonal protein, 5.0 g/dL
  • Serum kappa FLC, 240.0 mg/L
  • FISH: (+) IGH Translocations; none
  • ECOG PS 1
  • AG was diagnosed with R-ISS stage II/R2-ISS stage III IgG-kappa myeloma.
    • CAR T eligible

Treatment:

  • Patient was initiated on daratumumab/bortezomib/ lenalidomide/ dexamethasone (D-VRd) induction therapy prior to receiving ASCT, followed by lenalidomide maintenance therapy.
    • She achieved VGPR post-induction, and
    • Maintained VGPR post-ASCT
Related Videos
Related Content